Cancer-testis gene expression profile in human melanoma cell lines

被引：2

作者：

Misyurin V.A. ^{[1
,2
]}

Misyurin A.V. ^{[1
,2
]}

Lukina A.E. ^{[3
]}

Krutov A.A. ^{[2
]}

Kesaeva L.A. ^{[2
]}

Soldatova I.N. ^{[2
]}

Akhlynina T.V. ^{[1
,2
]}

Lyzhko N.A. ^{[1
,2
]}

Burova O.S. ^{[2
]}

Morozova L.F. ^{[2
]}

Mikhaylova I.N. ^{[2
]}

Baryshnikova M.A. ^{[2
]}

Baryshnikov A.Yu. ^{[2
]}

机构：

[1] Federal Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology, Moscow, 117997, ul. Samory Mashela, 1

[2] Blokhin Russian Cancer Research Center, Moscow, 115478, Kashirskoe shosse

[3] Hematological Research Center, Moscow, 125167, Novyi Zykovskii proezd

来源：

Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology | 2014年 / 8卷 / 3期

关键词：

cancer-testis antigens; cell lines; gene expression; immunotherapy; melanoma;

D O I：

10.1134/S1990747814020056

中图分类号：

学科分类号：

摘要：

A growing number of evidence indicates that cancer-testis antigens (CTA) can be used as specific targets for immune therapy of malignant melanoma. The aim of this study was to provide a basis for selecting the most suitable CTA by analyzing the mRNA expression profile of genes encoding CTA in melanoma cell lines. We used a real-time quantitative PCR to measure the expression level for the following genes: GAGE1, NY-ESO-1, MAGEA1, PASD, SCP1, SEMG1, SPANXA, SSX1, and PRAME. The objects of study were cell lines mel P, mel Si, mel Mtp, mel Il, mel Hn, mel Ibr, and mel Kor obtained from patients diagnosed with disseminated melanoma. We established that the highest frequency of occurrence and the highest expression level had the following genes: GAGE1, NY-ESO-1, MAGEA1, SCP1, SPANXA, SSX1, and PRAME. Their mRNA translation products can be promising candidates for immunotherapy. © 2014 Pleiades Publishing, Ltd.

引用

页码：240 / 244

页数：4

共 22 条

[1]

Demidov L.V., Harkevich G.Ju., Haljastov I.N., Pirogova N.A., Effectiveness of preventive chemotherapy in patients with melanoma with surgically treated metastases to regional lymph nodes, Novoe V Onkologii. Sbornik Nauchnykh Trudov (Rus.), 5, pp. 116-121, (2001)

[2]

Trapeznikov N.N., Demidov L.V., Haljastov I.N., Harkevich G.Ju., Bogdanov V.E., Pirogova N.A., Effectiveness of preventive chemotherapy with DTIC and aranoza-treated patients with regional metastatic melanoma, Vestn. RONC Im. N.N. Blokhina RAMN (Rus.), 1, pp. 77-80, (1998)

[3]

Artamonova E.V., Nadezhdina T.M., Borodkina A.G., Manzjuk L.V., Aranoza and cycloplatam in combination in treat disseminated melanoma, Ros. Bioterapevticheskij Zhurnal (Rus.), 1, 2, (2002)

[4]

Davydov M.I., Aksel E.M., The incidence of malignant diseases, Vestnik RONC Im. N.N. Blohina RAMN (Rus.), 17, 1, pp. 45-77, (2006)

[5]

Novik A.V., Skin melanoma: New approaches, Prakticheskaya Onkologia (Rus.), 12, 1, pp. 36-42, (2011)

[6]

Lipson E.J., Re-orienting the immune system: Durable tumor regression and successful re-induction-therapy using anti-PD1 antibodies, Oncoimmunology., 2, 4, (2013)

[7]

Mackiewicz J., What is new in the treatment of advanced melanoma? State of the art, Contemp. Oncol. (Pozn), 16, 5, pp. 363-370, (2012)

[8]

Baryshnikov A.Yu., Dendritic-cell based cancer vaccines, Vestn. RONC Im. N.N. Blohina RAMN (Rus.), 12, 2, pp. 50-54, (2001)

[9]

Baryshnikov A.Yu., Principles and practice of vaccine, Vestnik RAMN (Rus.), 12, pp. 6-12, (2004)

[10]

Manina I.V., Saprykina N.S., Kozlov A.M., Mihajlova I.N., Grigor'Eva I.N., Kasatkina N.N., Baryshnikov A.Yu., Improving the efficiency of tumor vaccine based on GM-CSF-secreting cell by preincubation with cytokines, Vestn. RONC Im. N.N. Blohina RAMN (Rus.), 3, 10, pp. 61-66, (2011)

← 1 2 3 →